US Stock MarketDetailed Quotes
SONN Sonnet BioTherapeutic
- 5.9100
- -0.2000-3.27%
Close Oct 18 16:00 ET
- 6.2700
- +0.3600+6.09%
Post 20:01 ET
3.84MMarket Cap-6156P/E (TTM)
6.5100High5.9016Low10.95KVolume6.0900Open6.1100Pre Close67.61KTurnover1.96%Turnover RatioLossP/E (Static)650.31KShares18.800052wk High1.47P/B3.30MFloat Cap4.370052wk Low--Dividend TTM558.32KShs Float329609.2800Historical High--Div YieldTTM9.96%Amplitude4.3700Historical Low6.1760Avg Price1Lot Size
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
Sonnet BioTherapeutic Stock Forum
Sonnet BioTherapeutics Inc. Regains Compliance with Nasdaq
Sonnet BioTherapeutics Inc. Enters into Licensing Agreement with Alkem Laboratories Limited to Develop and Commercialize SON-080 for Diabetic Peripheral Neuropathy (DPN) in India
Sonnet BioTherapeutics (NASDAQ: SONN) has entered into a licensing agreement with Alkem Laboratories for the development and commercialization of SON-080 for Diabetic Peripheral Neuropathy (DPN) in India. Sonnet will receive $1.0 million upfront and up to an additional $1.0 million i...
Sonnet Biotherapeutics: To Get Proceeds From Sale of New Jersey Nols & R&D Tax Credits Before End of Q1 2025
No comment yet